Pfizer’s US Rituximab Launched At A 24% Discount
Trastuzumab Will Launch Next Month With A 22% Lower Price
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
You may also be interested in...
Amgen has received FDA approval and revealed launch plans for its Riabni rituximab rival to Rituxan, setting a price discount in line with Pfizer’s Ruxience version. However, the biosimilar has not been approved for the rheumatoid arthritis indication that is enjoyed by Teva and Celltrion’s higher-priced Truxima version.
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.
Teva and Celltrion’s Truxima rituximab biosimilar is now available with a rheumatoid arthritis indication in the US, the firms have revealed, giving it a potential advantage over Pfizer’s Ruxience version.